ERYTHROPOIETIN DRUGS MARKET ANALYSIS

Market News

Key Developments

1. Major market players in the market are involved in various growth strategies such as applying for regulatory approval from concerning authorities, in order to gain competitive edge in the global market. For instance, in August 2019, GlaxoSmithKline plc (GSK) filed submission for market approval of Japanese New Drug Application (JNDA) to the Ministry of Health, Labour, and Welfare for its dapordustat. It is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment renal anemia caused in chronic key disease. Anemia in CKD is caused by deficiency of erythropoietin
2. Key companies in the market are involved in various business strategies such as gaining product approval from regulatory authorities, in order to expand their product portfolio. For instance, in May 2018, Pfizer, Inc., a U.S.-based pharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for RETACRIT, which is a biosimilar to Epogen and Procrit. It is the first and only FDA approved biosimilar erythropoiesis-stimulating agent.